Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600384 | 1.00 | POLB (0.48) | POLBKMT2ACYP2A6MAOAMAOB | |
| SCHEMBL3992123 | 0.91 | POLB (0.52) | POLBKMT2AALDH1A1HTTELANE | |
| SCHEMBL454827 | 0.81 | POLB (0.67) | POLBKMT2AMAOAMAOBHTT | |
| SCHEMBL25210408 | 0.79 | ALDH1A1 (0.39) | POLBKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL28160078 | 0.78 | POLB (0.64) | POLBKMT2AMAOAMAOBHTT | |
| SCHEMBL2022462 | 0.78 | POLB (0.64) | POLBKMT2AMAOAMAOBHTT | |
| SCHEMBL30718167 | 0.77 | DDB1 (0.44) | POLBKMT2AALDH1A1MEN1MAPT | |
| SCHEMBL29569183 | 0.74 | KMT2A (0.67) | KMT2ACYP2A6MAOAMAOBALDH1A1 | |
| SCHEMBL23832541 | 0.74 | KMT2A (0.67) | KMT2ACYP2A6MAOAMAOBALDH1A1 | |
| SCHEMBL11606022 | 0.72 | POLB (0.47) | POLBKMT2AALDH1A1ELANEGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197791-A1 | Method for the preparation of dicarboxylic lmides | SIEGFRIED LTD. (CH) | 2007-08-23 | — | — | US | claimed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-12030947-B2 | Humanized and affinity matured antibodies to FcRH5 and methods of use | GENENTECH, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240190966-A1 | ANTI-LY6G6D ANTIBODIES AND METHODS OF USE | GENENTECH INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2024091991-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE MYELOMA | GENENTECH, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240142437-A1 | METHODS TO PREVENT TERATOGENICITY OF IMID LIKE MOLECULES AND IMID BASED DEGRADERS/PROTACS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-02 | — | — | US | disclosed |
| WO-2024020432-A1 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | GENENTECH, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024015897-A1 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | GENENTECH, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20240018245-A1 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | GENENTECH INC (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4299073-A2 | HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FCRH5 AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | PROMETIC PHARMA SMT LIMITED (GB) | 2007-06-28 | — | — | US | disclosed |
| CN-1961876-A | Use of phthalimide derivative in preparation of anti-neovascularization medicine | BEIJING ENHUA ACADEMY OF MEDIC (CN) | 2007-05-16 | — | — | CN | disclosed |
| EP-1744749-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006136005-A1 | PURINE DERIVATIVES AND THEIR USE FOR TREATMENT OF AUTOIMMUNE DISEASES | PROMETIC BIOSCIENCES INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| WO-2005110408-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| EP-0984955-B1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNF ALPHA LEVELS | GELGENE CORP (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199677-A1 | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei | CELLECTIS (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-0914123-A4 | PRODRUGS OF THALIDOMIDE AND METHODS FOR USING SAME AS MODULATORS OF T-CELL FUNCTION | PROTOTEK INC (US) | 2000-10-11 | — | — | EP | disclosed |
| EP-0914123-A1 | PRODRUGS OF THALIDOMIDE AND METHODS FOR USING SAME AS MODULATORS OF T-CELL FUNCTION | PROTOTEK, INC. (US) | 1999-05-12 | — | — | EP | disclosed |
| WO-1997045117-A1 | PRODRUGS OF THALIDOMIDE AND METHODS FOR USING SAME AS MODULATORS OF T-CELL FUNCTION | PROTOTEK, INC. (US) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149528-A1 | Triazine dimers for the treatment of autoimmune diseases | SSB, TLR5, ICOS | POLB 3938/4885KMT2A 1471/4885CYP2A6 4478/4885 |
| US-20070197791-A1 | Method for the preparation of dicarboxylic lmides | RPL3, CCNH, CCNB3 | POLB 3256/4885KMT2A 2062/4885CYP2A6 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.